Work

Statins: in the beginning

Year: 2009

Type: article

Abstract: Since the first human trial of a hydroxymethylglutaryl-coenzyme A (HMG CoA) reductase inhibitor in 1978, the growth in importance of this drug class, both financially and medically, has been staggering. The aim of this paper is to summarise how this drug class was developed, highlighting the role ofAkira Endo.

Source: The Journal of the Royal College of Physicians of Edinburgh

DOI: 10.4997/jrcpe.2009.425

Authors: KS Lyons, M Harbinson

Institutions: Queen's University Belfast, Belfast Health and Social Care Trust

Language: English

Topic: Lipoproteins and Cardiovascular Health

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: Public Health Agency